
RSLS Valuation
ReShape Lifesciences Inc
- Overview
- Forecast
- Valuation
- Earnings
RSLS Relative Valuation
RSLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RSLS is overvalued; if below, it's undervalued.
Historical Valuation
ReShape Lifesciences Inc (RSLS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.64 is considered Fairly compared with the five-year average of -198.05. The fair price of ReShape Lifesciences Inc (RSLS) is between 3.10 to 32.39 according to relative valuation methord.
Relative Value
Fair Zone
3.10-32.39
Current Price:13.20
Fair
-0.01
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
ReShape Lifesciences Inc. (RSLS) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.01. The thresholds are as follows: Strongly Undervalued below -0.17, Undervalued between -0.17 and -0.08, Fairly Valued between 0.10 and -0.08, Overvalued between 0.10 and 0.19, and Strongly Overvalued above 0.19. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.90
EV/EBIT
ReShape Lifesciences Inc. (RSLS) has a current EV/EBIT of -0.90. The 5-year average EV/EBIT is -0.74. The thresholds are as follows: Strongly Undervalued below -3.77, Undervalued between -3.77 and -2.26, Fairly Valued between 0.77 and -2.26, Overvalued between 0.77 and 2.29, and Strongly Overvalued above 2.29. The current Forward EV/EBIT of -0.90 falls within the Historic Trend Line -Fairly Valued range.
0.64
PS
ReShape Lifesciences Inc. (RSLS) has a current PS of 0.64. The 5-year average PS is 0.96. The thresholds are as follows: Strongly Undervalued below -0.80, Undervalued between -0.80 and 0.08, Fairly Valued between 1.85 and 0.08, Overvalued between 1.85 and 2.73, and Strongly Overvalued above 2.73. The current Forward PS of 0.64 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
ReShape Lifesciences Inc. (RSLS) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.75. The thresholds are as follows: Strongly Undervalued below -3.53, Undervalued between -3.53 and -2.14, Fairly Valued between 0.64 and -2.14, Overvalued between 0.64 and 2.02, and Strongly Overvalued above 2.02. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
ReShape Lifesciences Inc. (RSLS) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.13. The thresholds are as follows: Strongly Undervalued below -1.27, Undervalued between -1.27 and -0.57, Fairly Valued between 0.83 and -0.57, Overvalued between 0.83 and 1.53, and Strongly Overvalued above 1.53. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
ReShape Lifesciences Inc (RSLS) has a current Price-to-Book (P/B) ratio of 0.42. Compared to its 3-year average P/B ratio of 0.68 , the current P/B ratio is approximately -37.85% higher. Relative to its 5-year average P/B ratio of 0.43, the current P/B ratio is about -2.14% higher. ReShape Lifesciences Inc (RSLS) has a Forward Free Cash Flow (FCF) yield of approximately -58.60%. Compared to its 3-year average FCF yield of -329.43%, the current FCF yield is approximately -82.21% lower. Relative to its 5-year average FCF yield of -234.90% , the current FCF yield is about -75.05% lower.
0.42
P/B
Median3y
0.68
Median5y
0.43
-58.60
FCF Yield
Median3y
-329.43
Median5y
-234.90
Competitors Valuation Multiple
The average P/S ratio for RSLS's competitors is 0.36, providing a benchmark for relative valuation. ReShape Lifesciences Inc Corp (RSLS) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -36.79%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RSLS decreased by 98.32% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -81.17 to -211.76.
The secondary factor is the Revenue Growth, contributed -36.79%to the performance.
Overall, the performance of RSLS in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch

TC
Token Cat Ltd
0.561
USD
+2.00%

YCBD
cbdMD Inc
0.670
USD
+4.04%

KTTA
Pasithea Therapeutics Corp
0.717
USD
+0.70%

SHPH
Shuttle Pharmaceuticals Holdings Inc
3.439
USD
+1.75%

CNET
ZW Data Action Technologies Inc
1.520
USD
+10.14%

PTIX
Protagenic Therapeutics Inc
4.240
USD
-0.47%

AQB
AquaBounty Technologies Inc
0.750
USD
+4.17%

FAMI
Farmmi Inc
1.730
USD
-0.57%

TNFA
TNF Pharmaceuticals Inc
0.063
USD
-17.31%

AZTR
Azitra Inc
0.923
USD
-2.84%
FAQ

Is ReShape Lifesciences Inc (RSLS) currently overvalued or undervalued?
ReShape Lifesciences Inc (RSLS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.64 is considered Fairly compared with the five-year average of -198.05. The fair price of ReShape Lifesciences Inc (RSLS) is between 3.10 to 32.39 according to relative valuation methord.

What is ReShape Lifesciences Inc (RSLS) fair value?

How does RSLS's valuation metrics compare to the industry average?

What is the current P/B ratio for ReShape Lifesciences Inc (RSLS) as of Aug 23 2025?

What is the current FCF Yield for ReShape Lifesciences Inc (RSLS) as of Aug 23 2025?

What is the current Forward P/E ratio for ReShape Lifesciences Inc (RSLS) as of Aug 23 2025?
